GlassScriptPhysician profile
Joseph Hubert Paul
NPI 1558387431
$186,186.75
in general payments reported to CMS, 2019-2025
15 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $12K · 2021: $10K · 2022: $27K · 2023: $23K · 2024: $12K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $5,200 · Travel and Lodging: $4,788 · Food and Beverage: $4,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,915.00 |
| Consulting Fee | $5,200.00 |
| Travel and Lodging | $4,788.35 |
| Food and Beverage | $4,328.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $87,913.80 | 2019-2023 | Symtuza |
| Gilead Sciences, INC. | $54,742.98 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $33,642.19 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Janssen Products, LP | $6,582.50 | 2019-2021 | |
| Janssen Biotech, INC. | $1,855.57 | 2020-2023 | Symtuza |
| Theratechnologies INC. | $563.95 | 2019-2023 | Egrifta, Trogarzo |
| Abbvie INC. | $502.23 | 2022-2025 | |
| Alkermes, INC. | $125.00 | 2019 | |
| Novo Nordisk INC | $68.93 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $45.72 | 2023 | Mounjaro |
| Pfizer INC. | $40.89 | 2019 | |
| Merck Sharp & Dohme LLC | $32.21 | 2025 | Pifeltro |
| Glaxosmithkline, LLC. | $28.85 | 2024 | Shingrix |
| Global Blood Therapeutics, INC. | $22.13 | 2021 | |
| Exact Sciences Corporation | $19.80 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.